Copyright
©The Author(s) 2022.
World J Cardiol. Jul 26, 2022; 14(7): 403-410
Published online Jul 26, 2022. doi: 10.4330/wjc.v14.i7.403
Published online Jul 26, 2022. doi: 10.4330/wjc.v14.i7.403
Figure 1 Left ventricular ejection fraction over trastuzumab cardiotoxicity monitor.
A: Total sample; B: Cardiotoxicity group. LVEF: Left ventricular ejection fraction.
Figure 2 Percentage of cardiac event over time.
OR: Odds ratio; CI: Confidence interval.
- Citation: Rala de Paula BH, Costa METF, de Sousa CAM, Bines J. Is there a window of opportunity to optimize trastuzumab cardiac monitoring? World J Cardiol 2022; 14(7): 403-410
- URL: https://www.wjgnet.com/1949-8462/full/v14/i7/403.htm
- DOI: https://dx.doi.org/10.4330/wjc.v14.i7.403